GlassScriptPhysician profile
Vijay Korimilli
NPI 1801091384
$1,727.57
in general payments reported to CMS, 2019-2025
23 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $80.64 · 2021: $221 · 2022: $362 · 2023: $353 · 2024: $209 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $328.64 | 2020-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $207.44 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $189.18 | 2021-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $147.71 | 2021-2023 | |
| Ceribell, INC. | $127.20 | 2025 | Pocket Eeg Device |
| Astrazeneca Pharmaceuticals LP | $83.38 | 2023-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $77.01 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $71.25 | 2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $66.31 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $59.44 | 2020-2022 | |
| Amarin Pharma, INC. | $41.28 | 2021-2022 | |
| Pfizer INC. | $40.52 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $39.69 | 2021-2023 | Seglentis, Livalo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.64 | 2025 | Caplyta |
| Abbvie INC. | $31.47 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.41 | 2022 | |
| Dexcom, INC. | $30.36 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $28.36 | 2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $26.41 | 2022 | |
| Optinose US, INC. | $17.95 | 2021 | |
| Genentech USA, INC. | $17.61 | 2020 | |
| Medtronic, INC. | $17.31 | 2025 | Intellis Adaptivestim |
| Sumitomo Pharma America, INC. | $14.00 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Korimilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.